Assertio (NASDAQ:ASRT) Releases Earnings Results

Assertio (NASDAQ:ASRT) announced its quarterly earnings data on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.02, Zacks reports. The company had revenue of $29.20 million during the quarter, compared to analysts’ expectations of $29.29 million. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. During the same quarter in the prior year, the company posted ($0.01) EPS.

Assertio Stock Performance

ASRT traded up $0.01 during trading on Wednesday, hitting $0.86. The stock had a trading volume of 703,490 shares, compared to its average volume of 931,153. Assertio has a one year low of $0.73 and a one year high of $1.80. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.51. The company has a 50 day moving average price of $1.13 and a 200-day moving average price of $1.18. The firm has a market cap of $81.80 million, a price-to-earnings ratio of -1.18 and a beta of 0.83.

Wall Street Analysts Forecast Growth

Separately, Maxim Group began coverage on shares of Assertio in a report on Friday, July 26th. They set a “buy” rating and a $3.00 price objective for the company. One analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $3.25.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.